Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director | December 08, 2020 | December 10, 2020 |
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Director | August 30, 2023 | September 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odonate Therapeutics, Inc.
Report date December 08, 2020 · Filed December 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2030-12-08 | Direct | 15,000 |
Reported balance
After 2020-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-08 · Grant · Acquired 15,000 · Balance 15,000 F1: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
TuHURA Biosciences, Inc./NV
Report date August 30, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2033-08-30 | Direct | 8,500 |
Reported balance
After 2023-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-30 · Grant · Acquired 8,500 · Balance 8,500 F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 1
1 source rowRow 1 · 2022-08-22 · Disposition to issuer · Disposed 500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 13,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.84 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 13,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.24 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.10 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2023 Filed Sep 1, 2023 22:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001493152-23-031538 · ownership.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-08-30 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.81 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 11 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.53 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 10 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 9 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $5.99 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 8 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $28.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 7 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $19.19 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 6 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $28.24 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 5 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $19.69 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 4 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | Not disclosed Strike: $10.84 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 3 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,500 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · derivative · entry 2 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerCommon Stock | 500 | $6.23 | $3,115.00 |
DisclosureSEC source: 0000899243-22-029651 · doc4.xml · nonDerivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:05 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001493152-22-018526 · ownership.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 21:00 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-22-003403 · doc4.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-12 F1 · derivative.exercise_date: The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:06 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | PurchaseCommon Stock | 3,000 | $0.74 | $2,226.90 |
DisclosureSEC source: 0000899243-21-046043 · doc4.xml · nonDerivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:31 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-21-001219 · kintara_fm4sep222021.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-09-22 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000920465-20-000162 · wf-form4_160798067443413.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:05 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0001209191-20-062688 · doc4.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 00:59 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000961 · kintara_fm4sep152020.xml · derivative · entry 1 Johnson Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 16:09 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0000920465-19-000182 · wf-form4_157713533716932.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on December 20, 2020. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 18:21 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $30.51 | $0.00 |
DisclosureSEC source: 0001209191-19-060279 · doc4.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-12-10 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000920465-19-000019 · wf-form4_154847143154709.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 23, 2020. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:08 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001209191-19-001523 · doc4.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-12-31 F1 · derivative.exercise_date: The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:17 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $15.79 | $0.00 |
DisclosureSEC source: 0001209191-18-061249 · doc4.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-12-03 F1 · derivative.exercise_date: The stock options vest with respect to 25% of the underlying shares on 12/03/2019, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $6.00 Strike: $6.00 | $3,000.00 |
DisclosureSEC source: 0000920465-18-000019 · wf-form4_152790193416176.xml · derivative · entry 2 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 500 shares Expires 2023-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionCommon Stock | 500 | $6.00 | $3,000.00 |
DisclosureSEC source: 0000920465-18-000019 · wf-form4_152790193416176.xml · nonDerivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000920465-18-000002 · wf-form4_151503452964254.xml · derivative · entry 5 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 4,000 shares Expires 2023-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $10.84 | $0.00 |
DisclosureSEC source: 0000920465-18-000002 · wf-form4_151503452964254.xml · derivative · entry 4 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 10,000 | $32.32 | $323,208.00 |
DisclosureSEC source: 0000920465-18-000002 · wf-form4_151503452964254.xml · nonDerivative · entry 3 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionCommon Stock | 4,000 | $6.00 | $24,000.00 |
DisclosureSEC source: 0000920465-18-000002 · wf-form4_151503452964254.xml · nonDerivative · entry 2 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionCommon Stock | 6,000 | $10.84 | $65,040.00 |
DisclosureSEC source: 0000920465-18-000002 · wf-form4_151503452964254.xml · nonDerivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0000920465-17-000077 · wf-form4_151321712188537.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on December 11, 2018. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:23 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0000920465-17-000016 · wf-form4_148374497590317.xml · derivative · entry 1 Douglass Laura L. · CIK 0001589362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 4, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.